- $19.32bn
- $20.09bn
- CA$2.59bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,863 | 1,800 | 1,475 | 1,868 | 2,588 |
Cost of Revenue | |||||
Gross Profit | 242 | 106 | 1.93 | 233 | 562 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,718 | 1,841 | 1,590 | 1,830 | 2,305 |
Operating Profit | 145 | -41.4 | -115 | 37.9 | 283 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 135 | -39.5 | -104 | 84.8 | 487 |
Provision for Income Taxes | |||||
Net Income After Taxes | 73.9 | -53.2 | -103 | 89.3 | 361 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 74 | -53.2 | -103 | 89.4 | 361 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 74 | -53.2 | -103 | 89.4 | 361 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.116 | -0.194 | -0.286 | 0.186 | 0.833 |
Dividends per Share |